TY - JOUR
T1 - Severe Cytokine Release Syndrome and Immune Effector Cell-associated Neurotoxicity Syndrome in a Man Receiving Immune Checkpoint Inhibitors for Lung Cancer
AU - Tanaka, Takaaki
AU - Taoka, Masataka
AU - Makimoto, Go
AU - Ninomiya, Kiichiro
AU - Higo, Hisao
AU - Fujii, Masanori
AU - Ichihara, Eiki
AU - Ohashi, Kadoaki
AU - Hotta, Katsuyuki
AU - Tabata, Masahiro
AU - Maeda, Yoshinobu
N1 - Publisher Copyright:
© 2024 The Japanese Society of Internal Medicine.
PY - 2024
Y1 - 2024
N2 - A 55-year-old man with stage IV lung adenocarcinoma was treated with cisplatin, pemetrexed, nivolumab, and ipilimumab. Approximately 100 days after treatment initiation, he became disoriented and presented to the emergency department with a high fever. Blood tests revealed liver and kidney dysfunctions. Subsequently, the patient developed generalized convulsions that required intensive care. He was clinically diagnosed with cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Organ damage was gradually controlled with immunosuppressive drugs, including steroids, and the patient was discharged. Successful treatment is rare in patients with CRS, including ICANS, during immune checkpoint inhibitor treatment for solid tumors.
AB - A 55-year-old man with stage IV lung adenocarcinoma was treated with cisplatin, pemetrexed, nivolumab, and ipilimumab. Approximately 100 days after treatment initiation, he became disoriented and presented to the emergency department with a high fever. Blood tests revealed liver and kidney dysfunctions. Subsequently, the patient developed generalized convulsions that required intensive care. He was clinically diagnosed with cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Organ damage was gradually controlled with immunosuppressive drugs, including steroids, and the patient was discharged. Successful treatment is rare in patients with CRS, including ICANS, during immune checkpoint inhibitor treatment for solid tumors.
KW - cytokine release syndrome
KW - immune checkpoint inhibitor
KW - immune effector cell-associated neurotoxicity syndrome
KW - ipilimumab
KW - nivolumab
UR - http://www.scopus.com/inward/record.url?scp=85176115684&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85176115684&partnerID=8YFLogxK
U2 - 10.2169/internalmedicine.2429-23
DO - 10.2169/internalmedicine.2429-23
M3 - Article
C2 - 37722894
AN - SCOPUS:85176115684
SN - 0918-2918
VL - 63
SP - 1261
EP - 1267
JO - Internal Medicine
JF - Internal Medicine
IS - 9
ER -